<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01349673</url>
  </required_header>
  <id_info>
    <org_study_id>BFPS3073</org_study_id>
    <nct_id>NCT01349673</nct_id>
  </id_info>
  <brief_title>The Safety and Tolerability of Budesonide Foam in Subjects With Active Ulcerative Proctitis or Proctosigmoiditis</brief_title>
  <official_title>A Phase 3, Open Label, Multicenter Study to Assess the Safety and Tolerability of Budesonide Foam in Subjects With Active Ulcerative Proctitis or Proctosigmoiditis</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Valeant Pharmaceuticals International, Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Valeant Pharmaceuticals International, Inc.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to evaluate safety and tolerability of cyclically dosed rectal
      budesonide foam in subjects with active ulcerative proctitis (UP) or ulcerative
      proctosigmoiditis (UPS).
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This is a Phase 3, multicenter, open label study in subjects who have participated previously
      in a Salix-sponsored budesonide rectal foam study for the treatment of ulcerative proctitis
      or proctosigmoiditis. Approximately 300 subjects will be enrolled into the study and receive
      budesonide foam cyclically for 6 weeks (BID for 2 weeks and QD for 4 weeks) each time they
      have an ulcerative proctitis or proctosigmoiditis flare. The study will continue until
      regulatory approval of budesonide foam occurs, or the sponsor decides to terminate the study.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>June 2011</start_date>
  <completion_date type="Actual">January 2015</completion_date>
  <primary_completion_date type="Actual">December 2014</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>To evaluate safety and tolerability of cyclically dosed rectal budesonide foam in subjects who present with a diagnosis of active ulcerative proctitis (UP) or ulcerative proctosigmoiditis (UPS).</measure>
    <time_frame>6 weeks</time_frame>
    <description>The following safety endpoints will be assessed throughout the study for each treatment group:
Incidence of treatment-emergent adverse events (AEs) and serious adverse events (SAEs), grouped by body system, relationship to study medication, and severity.
Changes from baseline in clinical laboratory assessments: urinalysis, hematology, and clinical chemistry.
Changes from baseline in vital sign assessments.
Changes from baseline in physical examination findings.</description>
  </primary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">114</enrollment>
  <condition>Proctitis</condition>
  <condition>Proctosigmoiditis</condition>
  <arm_group>
    <arm_group_label>Budesonide foam</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>2mg/25ml BID for 2 weeks followed by 2mg/25ml QD for 4weeks</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Budesonide Foam</intervention_name>
    <description>2mg/25ml BID for 2 weeks followed by 2mg/25ml QD for 4weeks</description>
    <arm_group_label>Budesonide foam</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Male or non-pregnant, non breast-feeding females â‰¥ 18 years old.

          -  Subject has previously been diagnosed with active mild to moderate UP/UPS and is
             currently experiencing symptoms of active UP/UPS disease after having completed
             participation in Salix's BUCF3001 or BUCF3002 study.

          -  Willingness to undergo sigmoidoscopy.

        Exclusion Criteria:

          -  Active systemic, ocular or cutaneous infection (e.g., parasitic, fungal, amoebic,
             viral or bacterial disease).

          -  History of sclerosing cholangitis, cirrhosis, or hepatic impairment, including chronic
             hepatitis of any etiology.

          -  Subject has taken systemic, inhaled, oral, topical or rectal corticosteroids (other
             than budesonide rectal foam) within 7 days of starting a treatment cycle.

          -  Subject has taken ketoconazole and other potent CYP3A4 inhibitors within 7 days of
             starting a treatment cycle.

          -  Subjects who take diuretics with cardiac glycosides.

          -  Unstable significant cardiovascular, hepatic, renal, endocrine, neurologic or
             pulmonary disease.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Gastroenterology Consultants, PA</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <zip>77034</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>January 2015</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>May 4, 2011</study_first_submitted>
  <study_first_submitted_qc>May 5, 2011</study_first_submitted_qc>
  <study_first_posted type="Estimate">May 6, 2011</study_first_posted>
  <last_update_submitted>January 26, 2015</last_update_submitted>
  <last_update_submitted_qc>January 26, 2015</last_update_submitted_qc>
  <last_update_posted type="Estimate">January 27, 2015</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Open-label</keyword>
  <keyword>Proctitis</keyword>
  <keyword>Proctosigmoiditis</keyword>
  <keyword>Ulcerative</keyword>
  <keyword>Salix</keyword>
  <keyword>Budesonide foam</keyword>
  <keyword>Budesonide</keyword>
  <keyword>Rectal</keyword>
  <keyword>Gastrointestinal</keyword>
  <keyword>Colitis</keyword>
  <keyword>UC</keyword>
  <keyword>UP</keyword>
  <keyword>UPS</keyword>
  <keyword>Additional relevant MeSH terms:</keyword>
  <keyword>Proctocolitis</keyword>
  <keyword>Ulcer</keyword>
  <keyword>Colitis, Ulcerative</keyword>
  <keyword>Gastroenteritis</keyword>
  <keyword>Gastrointestinal Diseases</keyword>
  <keyword>Digestive System Diseases</keyword>
  <keyword>Rectal Diseases</keyword>
  <keyword>Intestinal Diseases</keyword>
  <keyword>Colonic Diseases</keyword>
  <keyword>Sigmoid Diseases</keyword>
  <keyword>Pathologic Processes</keyword>
  <keyword>Inflammatory Bowel Diseases</keyword>
  <keyword>Bronchodilator Agents</keyword>
  <keyword>Autonomic Agents</keyword>
  <keyword>Peripheral Nervous System Agents</keyword>
  <keyword>Physiological Effects of Drugs</keyword>
  <keyword>Pharmacologic Actions</keyword>
  <keyword>Anti-Asthmatic Agents</keyword>
  <keyword>Respiratory System Agents</keyword>
  <keyword>Therapeutic Uses</keyword>
  <keyword>Glucocorticoids</keyword>
  <keyword>Hormones</keyword>
  <keyword>Hormones, Hormone Substitutes and Hormone Antagonists</keyword>
  <keyword>Anti-inflammatory Agents</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Ulcer</mesh_term>
    <mesh_term>Proctitis</mesh_term>
    <mesh_term>Proctocolitis</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Budesonide</mesh_term>
    <mesh_term>Peripheral Nervous System Agents</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

